Scinai Immunotherapeutics (SCNI) Non Operating Interest Expenses (2015 - 2022)

Scinai Immunotherapeutics has disclosed Non Operating Interest Expenses across 8 years of filings, most recently posting $3.4 million for Q4 2022.

• In Q4 2022, Non Operating Interest Expenses fell 60.06% year-over-year to $3.4 million; the TTM figure through Dec 2022 stood at -$7.1 million (down 461.57% YoY), while the FY2023 annual figure was $941000.0, up 4380.95% from the prior year.
• Non Operating Interest Expenses came in at $3.4 million for Q4 2022 at Scinai Immunotherapeutics, up from -$6.2 million in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $8.6 million in Q4 2021 to a low of -$14.4 million in Q4 2020.
• Average Non Operating Interest Expenses over 5 years is -$1.6 million, with a median of -$737000.0 recorded in 2022.
• Year-over-year, Non Operating Interest Expenses sank 2147.43% in 2019 and jumped 159.89% in 2021.
• Over 5 years, Non Operating Interest Expenses stood at -$460000.0 in 2018, then plunged by 30.65% to -$601000.0 in 2019, then slumped by 2299.83% to -$14.4 million in 2020, then jumped by 159.89% to $8.6 million in 2021, then slumped by 60.06% to $3.4 million in 2022.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $3.4 million in Q4 2022, -$6.2 million in Q3 2022, and -$3.6 million in Q2 2022.